{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:20:07Z","timestamp":1771482007801,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate whether methotrexate (MTX) use is associated with bone mineral density (BMD) in patients with polymyalgia rheumatica (PMR) and various forms of vasculitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Rh-GIOP is a cohort study designed to evaluate bone health in patients with inflammatory rheumatic diseases. This cross-sectional analysis assessed the baseline visits of all patients with PMR or any kind of vasculitis. Following univariable analysis, multivariable linear regression analysis was performed. The lowest T-score of either the lumbar spine or the femur was chosen as the dependent variable to examine the relationship between MTX use and BMD. These analyses were adjusted for a variety of potential confounders, including age, sex, and glucocorticoid (GC) intake.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 198 patients with PMR or vasculitis, 10 patients were excluded for very high GC dose (<jats:italic>n<\/jats:italic>\u2009=\u20096) or short disease duration (<jats:italic>n<\/jats:italic>\u2009=\u20094). The remaining 188 patients had the following diseases: PMR 37.2%, giant cell arteritis 25.0%, granulomatosis with polyangiitis 16.5%, followed by rarer diseases. The mean age was 68.0\u2009\u00b1\u200911.1\u00a0years, mean disease duration was 5.58\u2009\u00b1\u20096.39\u00a0years, and 19.7% had osteoporosis by dual x-ray absorptiometry (T-score\u2009\u2264\u2009\u22122.5). 23.4% were taking MTX at baseline with a mean dose of 13.2\u00a0mg\/week (median: 15\u00a0mg\/week). 38.6% of those used a subcutaneous preparation. MTX users had similar BMD compared to non-users (minimum T-scores \u22121.70 (\u00b1\u20090.86) versus \u22121.75 (\u00b1\u20090.91), respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.75). There was no statistically significant dose\u2013response relationship: neither current nor cumulative dose were associated with BMD in unadjusted or adjusted models (current dose: slope \u22120.02; \u22120.14 to 0.09; <jats:italic>p<\/jats:italic>\u2009=\u20090.69; cumulative dose: slope \u22120.12; \u22120.28 to 0.05; <jats:italic>p<\/jats:italic>\u2009=\u20090.15).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the Rh-GIOP cohort, MTX is used in about a quarter of patients with PMR or vasculitis. It is not associated with BMD levels.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00296-023-05286-6","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:02:47Z","timestamp":1677081767000},"page":"903-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides\u2014a cross-sectional analysis with dose\u2013response analyses"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3456-0597","authenticated-orcid":false,"given":"Andriko","family":"Palmowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3556-4709","authenticated-orcid":false,"given":"Mitsuteru","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4104-5080","authenticated-orcid":false,"given":"Burkhard","family":"Muche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-0688","authenticated-orcid":false,"given":"Zhivana","family":"Boyadzhieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-9559","authenticated-orcid":false,"given":"Sandra","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-4095","authenticated-orcid":false,"given":"Chikashi","family":"Terao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-0788","authenticated-orcid":false,"given":"Edgar","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"4","key":"5286_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","volume":"16","author":"F Buttgereit","year":"2020","unstructured":"Buttgereit F (2020) Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol 16(4):239\u2013246","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"5286_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12916-017-0987-1","volume":"16","author":"Z Paskins","year":"2018","unstructured":"Paskins Z, Whittle R, Sultan AA, Muller S, Blagojevic-Bucknall M, Helliwell T et al (2018) Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med 16(1):4","journal-title":"BMC Med"},{"issue":"3","key":"5286_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/cells11030536","volume":"11","author":"A Palmowski","year":"2022","unstructured":"Palmowski A, Wiebe E, Muche B, Hermann S, Dejaco C, Matteson EL et al (2022) Glucocorticoids are not associated with bone mineral density in patients with polymyalgia rheumatica, giant cell arteritis and other vasculitides-cross-sectional baseline analysis of the prospective Rh-GIOP cohort. Cells 11(3):536","journal-title":"Cells"},{"issue":"22","key":"5286_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1001\/archinte.166.22.2495","volume":"166","author":"G Schett","year":"2006","unstructured":"Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M et al (2006) High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 166(22):2495\u20132501","journal-title":"Arch Intern Med"},{"issue":"12","key":"5286_CR5","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00198-017-4189-7","volume":"28","author":"K Briot","year":"2017","unstructured":"Briot K, Geusens P, EmBultink I, Lems WF, Roux C (2017) Inflammatory diseases and bone fragility. Osteoporos Int 28(12):3301\u20133314","journal-title":"Osteoporos Int"},{"issue":"5","key":"5286_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00223-017-0335-7","volume":"102","author":"M G\u00fcler-Y\u00fcksel","year":"2018","unstructured":"G\u00fcler-Y\u00fcksel M, Hoes JN, Bultink IEM, Lems WF (2018) Glucocorticoids, inflammation and bone. Calcif Tissue Int 102(5):592\u2013606","journal-title":"Calcif Tissue Int"},{"issue":"13","key":"5286_CR7","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/jcm10132944","volume":"10","author":"J-W Kim","year":"2021","unstructured":"Kim J-W, Jung J-Y, Kim H-A, Suh C-H (2021) Anti-inflammatory effects of low-dose glucocorticoids compensate for their detrimental effects on bone mineral density in patients with rheumatoid arthritis. J Clin Med 10(13):2944","journal-title":"J Clin Med"},{"issue":"10","key":"5286_CR8","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S et al (2015) 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74(10):1799\u20131807","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5286_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E et al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19\u201330","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5286_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T et al (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75(9):1583\u20131594","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"5286_CR11","first-page":"2156","volume":"23","author":"K Maenaut","year":"1996","unstructured":"Maenaut K, Westhovens R, Dequeker J (1996) Methotrexate osteopathy, does it exist? J Rheumatol 23(12):2156\u20132159","journal-title":"J Rheumatol"},{"issue":"2","key":"5286_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/archderm.1996.03890260086013","volume":"132","author":"IM Zonneveld","year":"1996","unstructured":"Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ (1996) Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 132(2):184\u2013187","journal-title":"Arch Dermatol"},{"issue":"9","key":"5286_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00393-020-00855-7","volume":"79","author":"H M\u00f6nig","year":"2020","unstructured":"M\u00f6nig H, Ullrich S (2020) Gibt es eine MTX-induzierte Osteoporose? Z Rheumatol 79(9):898\u2013901","journal-title":"Z Rheumatol"},{"issue":"7","key":"5286_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","volume":"18","author":"J Pfeilschifter","year":"2000","unstructured":"Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18(7):1570\u20131593","journal-title":"J Clin Oncol"},{"key":"5286_CR15","unstructured":"Dachverband Osteologie (DVO). Prophylaxe, Diagnostik und Therapie der Osteoporose; 2017. Available from: https:\/\/dv-osteologie.org\/osteoporose-leitlinien. [Accessed 19. April 2022"},{"key":"5286_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222339","author":"E Wiebe","year":"2022","unstructured":"Wiebe E, Huscher D, Schaumburg D, Palmowski A, Hermann S, Buttgereit T et al (2022) Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222339","journal-title":"Ann Rheum Dis"},{"key":"5286_CR17","volume-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","author":"World Health Organization","year":"1994","unstructured":"World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group, Geneva"},{"issue":"2","key":"5286_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/00401706.1983.10487848","volume":"25","author":"B Rosner","year":"1983","unstructured":"Rosner B (1983) Percentage Points for a Generalized ESD Many-Outlier Procedure. Technometrics 25(2):165\u2013172","journal-title":"Technometrics"},{"issue":"3","key":"5286_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/acr.22429","volume":"67","author":"H Petri","year":"2015","unstructured":"Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N (2015) Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res 67(3):390\u2013395","journal-title":"Arthritis Care Res"},{"key":"5286_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151952","volume":"52","author":"N Ruffer","year":"2022","unstructured":"Ruffer N, Krusche M, Beil FT, Amling M, K\u00f6tter I, Rolvien T (2022) Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: a systematic review. Semin Arthritis Rheum 52:151952","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"5286_CR21","first-page":"1305","volume":"31","author":"O di Munno","year":"2004","unstructured":"di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M et al (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 31(7):1305\u20131309","journal-title":"J Rheumatol"},{"issue":"11","key":"5286_CR22","first-page":"2395","volume":"28","author":"AB Cranney","year":"2001","unstructured":"Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR et al (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28(11):2395\u20132399","journal-title":"J Rheumatol"},{"issue":"7","key":"5286_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","volume":"41","author":"NJ Minaur","year":"2002","unstructured":"Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK (2002) Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 41(7):741\u2013749","journal-title":"Rheumatology"},{"issue":"8","key":"5286_CR24","first-page":"1489","volume":"24","author":"LM Buckley","year":"1997","unstructured":"Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1997) Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 24(8):1489\u20131494","journal-title":"J Rheumatol"},{"issue":"3","key":"5286_CR25","first-page":"327","volume":"18","author":"M Mazzantini","year":"2000","unstructured":"Mazzantini M, Di Munno O, Incerti-Vecchi L, Pasero G (2000) Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate. Clin Exp Rheumatol 18(3):327\u2013331","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"5286_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/rheumatology\/keh072","volume":"43","author":"TC Barnes","year":"2004","unstructured":"Barnes TC, Daroszewska A, Fraser WD, Bucknall RC (2004) Bone turnover in untreated polymyalgia rheumatica. Rheumatology 43(4):486\u2013490","journal-title":"Rheumatology"},{"issue":"3","key":"5286_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105117","volume":"88","author":"G CarvajalAlegria","year":"2021","unstructured":"CarvajalAlegria G, Garrigues F, Bettacchioli E, Loeuille D, Saraux A, Cornec D et al (2021) Tocilizumab controls bone turnover in early polymyalgia rheumatica. Joint Bone Spine 88(3):105117","journal-title":"Joint Bone Spine"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05286-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05286-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05286-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T01:59:47Z","timestamp":1680746387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05286-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["5286"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05286-6","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"3 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP and ZB have no conflict of interest to disclose. FB reported receiving honoraria, travel expenses and grant\/research support from Medac and Pfizer. BM received honoraria and\/or travel support from Amgen, BMS, Galapagos, Gilead, Kyowa Kirin, Stadapharm and UCB. EW reported consultancy fees, honoraria and travel expenses from Medac and Novartis. SH received honoaria and\/ or travel support from Pfizer, Abbvie, and Medac.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}